Authors: J. Fialová 1,2; M. Kojanová 1 Authors‘ workplace: Dermatovenerologická klinika VFN a 1. LF UK, Praha, přednosta doc. MUDr. Ondřej Kodet, Ph. D. 1; Dermatovenerologická ambulance Nemocnice Milosrdných sester sv. Karla Boromejského v Praze, vedoucí lékař MUDr. Jorga Fialová 2 Published in: Čes-slov Derm, 101, 2026, No. 2, p. 51-62 Category: Reviews (Continuing Medical Education)
Hidradenitis suppurativa is a chronic, recurrent, inflammatory systemic disease characterized by painful nodules, abscesses, and sinus tracts in intertriginous areas. The disease significantly impairs quality of life and is associated with numerous comorbidities, particularly metabolic syndrome, cardiovascular diseases, and inflammatory bowel diseases. The pathogenesis of hidradenitis suppurativa is multifactorial and involves dysfunction of the follicular unit, activation of innate and adaptive immunity, and chronic inflammation leading to tissue destruction. Diagnosis is clinical, and disease severity is primarily assessed using the Hurley classification and the International Hidradenitis Suppurativa Severity Score System (IHS4). Current treatment includes topical therapy, systemic antibiotic therapy, biologic therapy targeting TNF-α and IL-17, and surgical removal of irreversible lesions. The goals of treatment are suppression of inflammation, prevention of tissue destruction, pain control, and improvement of patients’ quality of life. This review summarizes current knowledge on the epidemiology, pathogenesis, and comorbidities of hidradenitis suppurativa and proposes a practical therapeutic algorithm for outpatient dermatological practice.
Pathogenesis – comorbidities – biologic therapy – treatment – Hidradenitis suppurativa – acne inversa
1. ALMENARA-BLASCO M., GRACIA-CAZAÑA T., POBLADOR-PLOU B., LAGUNA-BERNA C., NAVARRO - -BIELSA A., MORENO-JUSTE A. et al. Multimorbidity of hidradenitis suppurativa: a cross-sectional population-based study of its associated comorbidities. Front Med (Lausanne), 2025, 12, 1618975.
2. ARENBERGEROVÁ M., FREY T., GKALPAKIOTIS S., ARENBERGER P. Hidradenitis suppurativa. Čes-slov Derm., 2011, 86 (1), s. 5–11.
3. BLUM F. R., MILES J. A., FARAG S. W., JOHNSON E. F., DAVIS M., HAMZAVI I. H. et al. Characterizing the immune checkpoint marker profiles of cutaneous squamous cell carcinomas in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol., 2023, 37, p. e316–e318.
4. CARTRON A., DRISCOLL M. S. Comorbidities of hidradenitis suppurativa: a review of the literature. Int J Womens Dermatol, 2019, 5(5), s. 330–334.
5. CIFERSKÁ H., VACHEK J. Diferenciální diagnostika bolestí zad. Vnitř Lék. 2022, 68(5), s. 332–341.
6. CROWLEY J. J., MEKKES J. R., ZOUBOULIS C. C., SCHEINFELD N., KIMBALL A., SUNDARAM M. et al. Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities. Br J Dermatol., 2014, 171(6), s. 1561–1565.
7. EBLE S. M., WISCO O. J., BOCCUTO L., LAFFIN B., PARKER V. G., DAVIS N. J. et al. Genetic factors associated with hidradenitis suppurativa: a literature review. Int J Womens Dermatol., 2024, 10:e158.
8. FIALOVÁ J., KOJANOVÁ M., ŠÁHÓ R., MAGNER M. Mucopolysaccharidosis type IVA and severe hidradenitis suppurativa: a case series. JAAD Case Rep., 2025, 62, s.146–150.
9. GAU S.Y., CHANG C. C., HSU W. T., CHU Y. J., KU Y. C., LIN H. et al. Risk of new-onset hidradenitis suppurativa in people with polycystic ovary syndrome: a large-scale propensity-score-matched cohort study. Int J Med Sci. 2025, 22(10), s. 2269–2276.
10. HOFFMAN L., HOU A., CHAITOWITZ M., LOWES M. A., COHEN S. R. Anemia in hidradenitis suppurativa. J Invest Dermatol. 2017, 137(Suppl 1), s. 40.
11. HURLEY H. J. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus: surgical approach. In: ROENIGHK R. K., ROENIGHK H. H., eds. Dermatologic Surgery: Principles and Practice. New York: Marcel Dekker. 1989, s. 729–739.
12. JEMEC G. B. E. Clinical practice. Hidradenitis suppurativa. N Engl J Med., 2012, 366, s. 158–164.
13. JFRI A., NASSIM D., O’BRIEN E., GULLIVER W., NIKOLAKIS G., ZOUBOULIS C. C. Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis. JAMA Dermatol., 2021, 157 (8), s. 924–931.
14. KIMBALL A. B., SOBELL J. M., ZOUBOULIS C. C., GU Y., WILLIAMS D. A., SUNDERAM M. et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled phase II study. J Am Acad Dermatol., 2012, 66 (2), s. 220–229.
15. KIMBALL A. B., JEMEC G. B. E., ALAVI A., REGUIAI Z., GOTTLIEB A. B., BECHARA F. G. et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet, 2023, 401, s. 747–761.
16. KIMBALL A. B., JEMEC G. B. E., SAYED C., KIRBY J. S., PRENS E., INGRAM J. R. et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet, 2024, 403, s. 2504–2519.
17. KIMBALL A. B., ACKERMAN L., SCHLOSSER B. J., PRAJAPATI V. H., FRETZIN S., TAKAHASHI H. et al. Efficacy and safety of upadacitinib in moderate-to-severe hidradenitis suppurativa: a phase 2 randomized, placebo-controlled study. J Am Acad Dermatol., 2023, 89 (Suppl), AB, p. 42.
18. KOJANOVÁ M., FIALOVÁ J., CETKOVSKÁ P., GKALPAKIOTIS S., MACHOVCOVÁ A., ŠTORK J. et al. Registr biologické/cílené léčby BIOREP – Souhrnná zpráva za rok 2024. Čes-slov Derm., 2025, 100(1), s. 13–40.
19. LIY-WONG C., POPE E., LARA-CORRALES I. Hidradenitis suppurativa in the pediatric population. J Am Acad Dermatol., 2015, 73(Suppl 1), s. S36–S41.
20. MANSILLA-POLO M., PONS-BENAVENT M., FERNÁNDEZ-CREHUET P., VILARRASA E., ALBANELL - -FERNÁNDEZ C., MORALES-TEDONE E. et al. Real - -world effectiveness and safety of bimekizumab for hidradenitis suppurativa. Australas J Dermatol., 2024, 65, e198–e202.
21. MINISTERSTVO ZDRAVOTNICTVÍ ČR, STÁTNÍ ÚSTAV PRO KONTROLU LÉČIV. BENEMYCIN 150 mg, 300 mg, tvrdé tobolky, souhrn údajů o přípravku (SPC). Praha, SÚKL; 2025. Dostupné z: https://prehledy. sukl.cz/prehled_leciv.html#/leciva/0093922. Citováno 26.2. 2026.
22. MINISTERSTVO ZDRAVOTNICTVÍ ČR, STÁTNÍ ÚSTAV PRO KONTROLU LÉČIV. BIMZELX 160 mg injekční roztok v předplněné injekční stříkačce, souhrn údajů o přípravku (SPC). Praha, SÚKL; 2025. Dostupné z: https://prehledy.sukl.cz/prehled_leciv.html#/leciva/0249582. Citováno 26.2. 2026.
23. MINISTERSTVO ZDRAVOTNICTVÍ ČR, STÁTNÍ ÚSTAV PRO KONTROLU LÉČIV. COSENTYX 75 mg/150 mg/ 300 mg injekční roztok, souhrn údajů o přípravku (SPC). Praha, SÚKL, 2025. Dostupné z: https://prehledy.sukl.cz/prehled_leciv.html#/leciva/0250237. Citováno 26.2. 2026.
24. MINISTERSTVO ZDRAVOTNICTVÍ ČR, STÁTNÍ ÚSTAV PRO KONTROLU LÉČIV. DOXYHEXAL 100 mg, tvrdé tobolky, souhrn údajů o přípravku (SPC). Praha, SÚKL, 2024. Dostupné z: https://prehledy.sukl. cz/prehled_leciv.html#/leciva/0032954. Citováno 26.2. 2026.
25. MINISTERSTVO ZDRAVOTNICTVÍ ČR, STÁTNÍ ÚSTAV PRO KONTROLU LÉČIV. HUMIRA 40 mg/0,4 ml injekční roztok v předplněné injekční stříkačce, souhrn údajů o přípravku (SPC). Praha, SÚKL, 2025. Dostupné z: https://prehledy.sukl.cz/prehled_leciv. html#/leciva/0193765. Citováno 26.2. 2026.
26. MOLINELLI E., BRISIGOTTI V., SIMONETTI O., CAMPANATI A., SAPIGNI C., D’AGOSTINO G. M. et al. Efficacy and safety of topical resorcinol 15% as long - -term treatment of mild-to-moderate hidradenitis suppurativa. Br J Dermatol., 2020, 183(6), s. 1117 – 1119.
27. NGUYEN T. V., DAMIANI G., ORENSTEIN L. A. V., HAMZAVI I., JEMEC G. B. E. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol., 2021, 35(1), s. 50–61.
28. NIGRO A. R., OSMAN A., CLELAND E., POVELAITIS M., HANDLER M. Z. The impact of hidradenitis suppurativa on sexual health: a systematic review. Dermatol Ther., 2025, s. 2247169.
29. SABAT R., ALAVI A., WOLK K., WORTSMAN X., MCGRATH B., GARG A. et al. Hidradenitis suppurativa. Lancet, 2025, 405(10385), s. 420–438.
30. SABAT R., TSAOUSI A., GHORESCHI K., WOLK K., SCHNEIDER-BURRUS S. Sex-disaggregated population analysis in patients with hidradenitis suppurativa. Front Med (Lausanne), 2022, 9, s. 1028943.
31. TZELLOS T., ZOUBOULIS C. C. Review of comorbidities of hidradenitis suppurativa: implications for daily clinical practice. Dermatol Ther (Heidelb), 2020, 10, s. 63–71.
32. TZELLOS T., ZOUBOULIS C. C. Which hidradenitis suppurativa comorbidities should I take into account? Exp Dermatol., 2022, 31(Suppl 1), s. 29–32.
33. TZELLOS T., VAN STRAALEN K. R., KYRGIDIS A., ALAVI A., GOLDFARB N., GULLIVER W. et al. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. J Eur Acad Dermatol Venereol., 2023, 37(2), s. 395–401.
34. TZUR BITAN D., BERZIN D., COHEN A. D. Hidradenitis suppurativa and schizophrenia: a nationwide cohort study. J Eur Acad Dermatol Venereol., 2020, 34(3), s. 574–579.
35. WRIGHT S., STRUNK A., GARG A. Prevalence of depression among children, adolescents, and adults with hidradenitis suppurativa. J Am Acad Dermatol., 2022, 86(1), s. 55–60.
36. ZOUBOULIS C. C., BECHARA F. G., FRITZ K., GOEBELER M., HETZER F. H., JUST E. et al. S2k guideline for the treatment of hidradenitis suppurativa/acne inversa. Akt Dermatol., 2024, 50, s. 30–83.
37. ZOUBOULIS C. C., BECHARA F. G., BENHADOU F., BETTOLI V., BUKVIĆ MOKOS Z., DEL MARMOL V. et al. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment. J Eur Acad Dermatol Venereol., 2025, 39, s. 899–941.
38. ZOUBOULIS C. C., BENHADOU F., BYRD A. S., CHANDRAN N. S., GIAMARELLOS-BOURBOULIS E. J., FABBROCINI G. et al. What causes hidradenitis suppurativa? – 15 years after. Exp Dermatol., 2020, 29(12), s. 1154–1170.
39. ZOUBOULIS C. C., DEL MARMOL V., MROWIETZ U., PRENS E. P., TZELLOS T., JEMEC G. B. E. Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology, 2015, 231(2), s. 184–190.
40. ZOUBOULIS C. C., OKUN M. M., PRINCE H. M., GU Y., SUNDERAM M., WILLIAMS D. A. et al. Long-term adalimumab efficacy in patients with moderate - -to-severe hidradenitis suppurativa/acne inversa. J Am Acad Dermatol., 2019, 80(1), s. 60–69.
41. ZOUBOULIS C. C., PASSERON T., PARISER D., WOZNIAK M. B., LI X., UHLMANN L. et al. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure. Br J Dermatol., 2024, 190, s. 836–845.
42. ZOUBOULIS C. C., TZELLOS T., KYRGIDIS A., JEMEC G. B. E., BECHARA F. G., GIAMARELLOS-BOURBOULIS E. J. et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS). Br J Dermatol., 2017, 177(5), s. 1401–1409.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
